{
    "clinical_study": {
        "@rank": "94251", 
        "arm_group": [
            {
                "arm_group_label": "AmnioClear\u2122", 
                "arm_group_type": "Active Comparator", 
                "description": "AmnioClear\u2122 Human Allograft Amniotic Membrane"
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "arm_group_type": "No Intervention", 
                "description": "Standard moist wound dressing (saline wet-to-moist or a hydrogel dressing)"
            }
        ], 
        "brief_summary": {
            "textblock": "This research project is testing a product called AmnioClear\u2122 which is an amniotic membrane\n      graft processed for Liventa Bioscience formerly AFCell Medical.  AmnioClear\u2122 allograft human\n      amniotic membrane is regulated solely under section 361 of the Public Health Service Act.\n\n      The purpose of the study is to see if this treatment works to accelerate the healing time of\n      chronic wounds."
        }, 
        "brief_title": "A Randomized Comparison of AmnioClear\u2122 Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds", 
        "condition": [
            "Diabetic Foot Ulcers", 
            "Wound Care"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Ulcer", 
                "Foot Ulcer", 
                "Diabetic Foot"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Stable Type I or II diabetes mellitus\n\n          -  At least one chronic diabetic ulcer\n\n          -  Full-thickness ulcer size from 1-8 cm2.\n\n        Exclusion Criteria:\n\n          -  Concurrent use of corticosteroids, NSAIDs immuno-suppressive or cytotoxic agents\n\n          -  Bleeding disorders\n\n          -  Ulcer with muscle, tendon, capsule or bone involvement"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02120755", 
            "org_study_id": "Amn-DFU-01"
        }, 
        "intervention": {
            "arm_group_label": "AmnioClear\u2122", 
            "intervention_name": "AmnioClear\u2122 Human Allograft Amniotic Membrane", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 22, 2014", 
        "location": {
            "contact": {
                "email": "cameron.howes@duke.edu", 
                "last_name": "Cameron Howes"
            }, 
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina"
                }, 
                "name": "Duke University"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Comparison of AmnioClear\u2122 Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Clinical assessment of wound healing in terms of the reduction in size and shape of the wound over time.", 
            "measure": "Reduction in Wound Size", 
            "safety_issue": "No", 
            "time_frame": "12 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02120755"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Liventa Bioscience", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Liventa Bioscience", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}